Literature DB >> 15579773

Forskolin, 8-Br-3',5'-cyclic adenosine 5'-monophosphate, and catalytic protein kinase A expression in the nucleus increase radioiodide uptake and sodium/iodide symporter protein levels in RET/PTC1-expressing cells.

Anjli Venkateswaran1, Derek K Marsee, Steven H Green, Sissy M Jhiang.   

Abstract

RET/PTC1, a thyroid-specific oncogene, has been reported to down-regulate sodium/iodide symporter (NIS) expression and function in vitro and in vivo. Recently, RET/PTC1 has been shown to interfere with TSH signaling at multiple levels in thyroid cells. The objective of this study was to investigate whether RET/PTC1-mediated NIS reduction can be rescued by activating cAMP-protein kinase A (PKA) pathways. We showed that both forskolin and 8-Br-cAMP increase radioiodide uptake and NIS protein in RET/PTC1-expressing cells to the same extent as the parental PC Cl 3 cells. We found that RET/PTC1 decreases nuclear localization of catalytic PKA, and forskolin treatment was able to counteract this RET/PTC1 effect. Furthermore, transient expression of catalytic PKA in the nucleus increased radioiodide uptake and NIS protein in RET/PTC1-expressing cells. Taken together, these studies suggest that RET/PTC1 down-regulates NIS expression by interrupting TSH/cAMP signaling, and this RET/PTC1 effect can be reversed by activating cAMP-PKA pathways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15579773     DOI: 10.1210/jc.2004-1414

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Sterol regulatory element-binding proteins are regulators of the NIS gene in thyroid cells.

Authors:  Robert Ringseis; Christine Rauer; Susanne Rothe; Denise K Gessner; Lisa-Marie Schütz; Sebastian Luci; Gaiping Wen; Klaus Eder
Journal:  Mol Endocrinol       Date:  2013-03-29

Review 2.  The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics.

Authors:  Takahiko Kogai; Gregory A Brent
Journal:  Pharmacol Ther       Date:  2012-06-29       Impact factor: 12.310

3.  Identification of cyclic adenosine 3',5'-monophosphate response element modulator as an activator of the human sodium/iodide symporter upstream enhancer.

Authors:  Mike S Fenton; Kenneth M Marion; Jerome M Hershman
Journal:  Endocrinology       Date:  2008-01-17       Impact factor: 4.736

Review 4.  Thyroid Carcinoma: Phenotypic Features, Underlying Biology and Potential Relevance for Targeting Therapy.

Authors:  Jinwei Hu; Isabella J Yuan; Saied Mirshahidi; Alfred Simental; Steve C Lee; Xiangpeng Yuan
Journal:  Int J Mol Sci       Date:  2021-02-16       Impact factor: 5.923

Review 5.  Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy.

Authors:  Jierui Liu; Yanqing Liu; Yansong Lin; Jun Liang
Journal:  Endocrinol Metab (Seoul)       Date:  2019-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.